title: Efficacy and safety of tacrolimus versus cyclosporine in kidney and pancreas transplant recipients.
authors.affiliation: University of Cincinnati Medical Center, Ohio, USA.
authors.forename: M
authors.initials: M
authors.lastname: el-Ghoroury
authors.forename: S
authors.initials: S
authors.lastname: Hariharan
authors.forename: V R
authors.initials: VR
authors.lastname: Peddi
authors.forename: R
authors.initials: R
authors.lastname: Munda
authors.forename: T J
authors.initials: TJ
authors.lastname: Schroeder
authors.forename: A M
authors.initials: AM
authors.lastname: Demmy
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: M R
authors.initials: MR
authors.lastname: First
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002096:C-Peptide / Q000097:blood; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D001379:Azathioprine; D001786:Blood Glucose; D002096:C-Peptide; D003404:Creatinine; D016572:Cyclosporine; D006442:Glycated Hemoglobin; D007166:Immunosuppressive Agents; D008775:Methylprednisolone; D016853:Muromonab-CD3; D016559:Tacrolimus